Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value. A one-time gene therapy with a durable safety and ...

D Molecular Therapeutics remains a Buy as 4D-150 enters phase 3 for wet AMD/DME, cutting injections up to 87%. Click for more ...

Please provide your email address to receive an email when new articles are posted on . The average number of annual injections decreased from 8.7 in year 1 to 4.7 in year 7. The regimen could reduce ...

BERKELEY, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced new data on VLTR-559, a long-acting ...

BERKELEY, Calif., May 04, 2026 (GLOBE NEWSWIRE)-- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the presentation of preclinical data ...

DENVER -- A sustained-release VEGF inhibitor implant outperformed standard anti-VEGF therapy for maintaining visual acuity in neovascular, or wet, age-related macular degeneration (AMD), showed a ...

Two investigational agents from Kodiak Sciences helped improve vision in patients with wet age-related macular degeneration, ...

The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...

In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami ...

MARINA Trial (2006) Ranibizumab is effective in wet AMD (minimal adverse effects) Randomized trial resulted in FDA approval of ranibizumab, the current first-line treatment for wet AMD ANCHOR Trial ...

Wet age-related macular degeneration (AMD), or advanced neovascular AMD, affects central vision and can lead to rapid, irreversible vision loss. It often requires treatment to preserve eyesight.